John J Turchi

List of Publications by Year
in descending order

90 papers	3,885 citations	117625 34 h-index	144013 57 g-index
94 all docs	94 docs citations	94 times ranked	4792 citing authors

#	Article	IF	Citations
1	In Vivo Targeting Replication Protein A for Cancer Therapy. Frontiers in Oncology, 2022, 12, 826655.	2.8	6
2	Characterization and initial demonstration of <i>inÂvivo</i> efficacy of a novel heat-activated metalloenediyne anti-cancer agent. International Journal of Hyperthermia, 2022, 39, 405-413.	2.5	0
3	Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. Frontiers in Oncology, 2022, 12, 850883.	2.8	12
4	Abstract 1406: Design and synthesis of novel cardiac glycosides by targeting the DNA damage response for cancer therapy. Cancer Research, 2022, 82, 1406-1406.	0.9	0
5	OB-Folds and Genome Maintenance: Targeting Proteinâ€"DNA Interactions for Cancer Therapy. Cancers, 2021, 13, 3346.	3.7	6
6	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell, 2021, 81, 3128-3144.e7.	9.7	142
7	Structure-Guided Optimization of Replication Protein A (RPA)â€"DNA Interaction Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1118-1124.	2.8	16
8	Discovery and development of novel DNA-PK inhibitors by targeting the unique Kuâ€"DNA interaction. Nucleic Acids Research, 2020, 48, 11536-11550.	14.5	19
9	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. Molecular Cancer Research, 2020, 18, 1699-1710.	3.4	9
10	Small-Molecule Inhibitor Screen for DNA Repair Proteins. Methods in Molecular Biology, 2019, 1999, 217-221.	0.9	1
11	Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku. , 2019, , .		0
12	Modulating DNA Repair Pathways to Improve Precision Genome Engineering. ACS Chemical Biology, 2018, 13, 389-396.	3.4	99
13	Characterization of Thermally Activated Metalloenediyne Cytotoxicity in Human Melanoma Cells. Radiation Research, 2018, 190, 107-116.	1.5	5
14	Abstract 2829: Targeting the DNA damage response and DNA-PK signaling via small molecule Ku inhibitors. , 2018, , .		2
15	Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Proteinâ€"DNA Interaction. Journal of Medicinal Chemistry, 2017, 60, 8055-8070.	6.4	12
16	Abstract LB-119: Targeting DNA-PK via small molecule inhibitors of the Ku-DNA interaction. , 2017, , .		0
17	Abstract 1416: Development of small molecule inhibitors for cancer therapy by targeting RPA and XPA nucleotide excision repair proteins. , 2017, , .		0
18	DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Repair, 2016, 40, 35-46.	2.8	45

#	Article	IF	Citations
19	DNA repair targeted therapy: The past or future of cancer treatment?. , 2016, 160, 65-83.		307
20	Chemical inhibitor targeting the replication protein Aâ€"DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochemical Pharmacology, 2015, 93, 25-33.	4.4	42
21	Recognition of DNA Termini by the C-Terminal Region of the Ku80 and the DNA-Dependent Protein Kinase Catalytic Subunit. PLoS ONE, 2015, 10, e0127321.	2.5	19
22	Testing the Metal of ERCC2 in Predicting the Response to Platinum-Based Therapy. Cancer Discovery, 2014, 4, 1118-1119.	9.4	1
23	Unraveling the Complexities of DNA-Dependent Protein Kinase Autophosphorylation. Molecular and Cellular Biology, 2014, 34, 2162-2175.	2.3	58
24	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. Clinical Cancer Research, 2014, 20, 6504-6516.	7.0	87
25	Exploring a structural proteinâ€"drug interactome for new therapeutics in lung cancer. Molecular BioSystems, 2014, 10, 581-591.	2.9	12
26	Extracellular Tissue Transglutaminase Activates Noncanonical NF-Î⁰B Signaling and Promotes Metastasis in Ovarian Cancer. Neoplasia, 2013, 15, 609-IN8.	5.3	52
27	Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochemical and Biophysical Research Communications, 2013, 439, 586-590.	2.1	33
28	Chemotherapy induced DNA damage response. Cancer Biology and Therapy, 2013, 14, 379-389.	3.4	216
29	Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.. , 2013, , .		2
30	Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. , 2012, , 109-117.		3
31	Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways. Journal of Biological Chemistry, 2012, 287, 24263-24272.	3.4	49
32	Abstract 4753: Targeting nucleotide excision repair: Chemical synthetic lethality and biology-based combination therapy. , 2012, , .		4
33	Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80. International Journal of Biochemistry and Molecular Biology, 2012, 3, 36-45.	0.1	6
34	Identification of Mre11 as a Target for Heat Radiosensitization. Radiation Research, 2011, 176, 323.	1.5	8
35	Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase. Molecular Cancer Therapeutics, 2011, 10, 626-636.	4.1	35
36	Interrogation of Nucleotide Excision Repair Capacity: Impact on Platinum-Based Cancer Therapy. Antioxidants and Redox Signaling, 2011, 14, 2465-2477.	5.4	18

#	Article	IF	Citations
37	Repair Of DNA Double-Strand Breaks By Non-Homologous End-Joining Is Independent Of Cisplatin-Induced Checkpoint Activation And Downstream Damage Response Pathways In A Non-Small Cell Lung Cancer Cell Culture Model. , 2011, , .		0
38	DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target. Clinical Cancer Research, 2011, 17, 6973-6984.	7.0	97
39	Coordination of DNAâ€“PK Activation and Nuclease Processing of DNA Termini in NHEJ. Antioxidants and Redox Signaling, 2011, 14, 2531-2543.	5.4	29
40	Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin. Molecular Cancer Therapeutics, 2011, 10, 1796-1806.	4.1	47
41	Current Advances in DNA Repair: Regulation of Enzymes and Pathways Involved in Maintaining Genomic Stability. Antioxidants and Redox Signaling, 2011, 14, 2461-2464.	5.4	1
42	Abstract 2320: In vivo characterization of small molecule inhibitors of replication protein A: Implications for cancer therapy. , 2011, , .		0
43	Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair. DNA Repair, 2010, 9, 670-677.	2.8	30
44	Targeting the OB-Folds of Replication Protein A with Small Molecules. Journal of Nucleic Acids, 2010, 2010, 1-11.	1.2	22
45	Cisplatin Sensitizes DNA To Ionizing Radiation By Impairing Non-Homologous End-Joining. , 2010, , .		0
46	Targeted Inhibition of Replication Protein A Reveals Cytotoxic Activity, Synergy with Chemotherapeutic DNA-Damaging Agents, and Insight into Cellular Function. Cancer Research, 2010, 70, 3189-3198.	0.9	73
47	Identification of Novel Small Molecule Inhibitors of the XPA Protein Using in Silico Based Screening. ACS Chemical Biology, 2010, 5, 953-965.	3.4	34
48	Photo-Cross-Linking of XPCâˆ'Rad23B to Cisplatin-Damaged DNA Reveals Contacts with Both Strands of the DNA Duplex and Spans the DNA Adduct. Biochemistry, 2010, 49, 669-678.	2.5	25
49	Intrinsic hTRF1 fluorescence quenching reveals details of telomere DNA binding activity: Impact of DNA length, structure and position of telomeric repeats. Archives of Biochemistry and Biophysics, 2010, 493, 207-212.	3.0	3
50	Telomerase-associated Protein 1, HSP90, and Topoisomerase IIÎ± Associate Directly with the BLM Helicase in Immortalized Cells Using ALT and Modulate Its Helicase Activity Using Telomeric DNA Substrates. Journal of Biological Chemistry, 2009, 284, 14966-14977.	3.4	47
51	Molecular analysis of Ku redox regulation. BMC Molecular Biology, 2009, 10, 86.	3.0	16
52	Targeting Nucleotide Excision Repair as a Mechanism to Increase Cisplatin Efficacy. , 2009, , 177-187.		3
53	Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Research, 2008, 18, 64-72.	12.0	242
54	A special issue on DNA damage responses and genome maintenance. Cell Research, 2008, 18, 1-2.	12.0	6

#	Article	IF	Citations
55	ATM mediates repression of DNA end-degradation in an ATP-dependent manner. DNA Repair, 2008, 7, 464-475.	2.8	18
56	DNA-Dependent Conformational Changes in the Ku Heterodimer. Biochemistry, 2008, 47, 4359-4368.	2.5	32
57	A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining. Nucleic Acids Research, 2008, 36, 4022-4031.	14.5	30
58	Pre-Steady-State Binding of Damaged DNA by XPCâˆ'hHR23B Reveals a Kinetic Mechanism for Damage Discriminationâ€. Biochemistry, 2006, 45, 1961-1969.	2.5	48
59	Kinetic Analysis of the Ku-DNA Binding Activity Reveals a Redox-dependent Alteration in Protein Structure That Stimulates Dissociation of the Ku-DNA Complex. Journal of Biological Chemistry, 2006, 281, 13596-13603.	3.4	40
60	Nitric oxide and cisplatin resistance: NO easy answers. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4337-4338.	7.1	32
61	Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Reports, 2005, 6, 83-89.	4.5	132
62	Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining. Molecular Cancer Research, 2005, 3, 277-285.	3.4	130
63	Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Research, 2005, 33, 152-161.	14.5	36
64	DNA Damage Induced Hyperphosphorylation of Replication Protein A. 2. Characterization of DNA Binding Activity, Protein Interactions, and Activity in DNA Replication and Repair. Biochemistry, 2005, 44, 8438-8448.	2.5	62
65	DNA Damage Induced Hyperphosphorylation of Replication Protein A. 1. Identification of Novel Sites of Phosphorylation in Response to DNA Damage. Biochemistry, 2005, 44, 8428-8437.	2.5	72
66	Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2. Human Molecular Genetics, 2004, 13, 1919-1932.	2.9	139
67	Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. Molecular Cancer Therapeutics, 2004, 3, 385-91.	4.1	32
68	RPA Phosphorylation in Mitosis Alters DNA Binding and Proteinâˆ'Protein Interactionsâ€. Biochemistry, 2003, 42, 3255-3264.	2.5	118
69	Interaction and Stimulation of Human FEN-1 Nuclease Activities by Heterogeneous Nuclear Ribonucleoprotein A1 in Î±-Segment Processing during Okazaki Fragment Maturationâ€. Biochemistry, 2003, 42, 15045-15052.	2.5	23
70	Behavior of T7 RNA Polymerase and Mammalian RNA Polymerase II at Site-specific Cisplatin Adducts in the Template DNA. Journal of Biological Chemistry, 2003, 278, 35791-35797.	3.4	86
71	Xeroderma Pigmentosum Complementation Group A Protein (XPA) Modulates RPA-DNA Interactions via Enhanced Complex Stability and Inhibition of Strand Separation Activity. Journal of Biological Chemistry, 2002, 277, 16096-16101.	3.4	75
72	Partial Reconstitution of Human DNA Mismatch Repair In Vitro: Characterization of the Role of Human Replication Protein A. Molecular and Cellular Biology, 2002, 22, 2037-2046.	2.3	75

#	Article	IF	Citations
73	Strand-Specific Binding of RPA and XPA to Damaged Duplex DNAâ€. Biochemistry, 2002, 41, 2402-2408.	2.5	68
74	DNA-Dependent Protein Kinase in Apoptosis. , 2001, 39, 693-700.		0
75	TRF1 Inhibits Telomere C-Strand DNA Synthesis in Vitro. Biochemistry, 2001, 40, 2426-2432.	2.5	14
76	Stopped-flow Kinetic Analysis of Replication Protein A-binding DNA. Journal of Biological Chemistry, 2001, 276, 22630-22637.	3.4	53
77	Overexpression and Purification of Human XPA Using a Baculovirus Expression System. Protein Expression and Purification, 2000, 19, 1-11.	1.3	24
78	Physiological functions of protein kinase inhibitors. Exs, 2000, 89, 109-121.	1.4	1
79	Replication Protein A (RPA) Binding to Duplex Cisplatin-damaged DNA Is Mediated through the Generation of Single-stranded DNA. Journal of Biological Chemistry, 1999, 274, 14972-14978.	3.4	92
80	Interactions of mammalian proteins with cisplatin-damaged DNA. Journal of Inorganic Biochemistry, 1999, 77, 83-87.	3.5	28
81	Effect of DNA Polymerases and High Mobility Group Protein 1 on the Carrier Ligand Specificity for Translesion Synthesis past Platinumâ^'DNA Adductsâ€. Biochemistry, 1999, 38, 11026-11039.	2.5	129
82	Human Replication Protein A Preferentially Binds Cisplatin-Damaged Duplex DNA in Vitroâ€. Biochemistry, 1998, 37, 8808-8815.	2.5	66
83	Synthesis of the Mammalian Telomere Lagging Strand in Vitro. Journal of Biological Chemistry, 1997, 272, 11678-11681.	3.4	24
84	Mechanism of DNA-Dependent Protein Kinase Inhibition by cis-Diamminedichloroplatinum(II)-Damaged DNA. Biochemistry, 1997, 36, 7586-7593.	2.5	42
85	High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1354, 279-290.	2.4	11
86	Cisplatinâ^'DNA Binding Specificity of Calf High-Mobility Group 1 Proteinâ€. Biochemistry, 1996, 35, 2992-3000.	2.5	34
87	Human Ku Autoantigen Binds Cisplatin-damaged DNA but Fails to Stimulate Human DNA-activated Protein Kinase. Journal of Biological Chemistry, 1996, 271, 13861-13867.	3.4	51
88	Effects of the anticancer drug cis-diamminedichloroplatinum(II) on the activities of calf thymus DNA polymerase .epsilon.. Biochemistry, 1993, 32, 841-848.	2.5	34
89	DNA substrate specificity of DNA helicase E from calf thymus. Nucleic Acids Research, 1992, 20, 6075-6080.	14.5	15
90	DNA helicase E and DNA polymerase .epsilon. functionally interact for displacement synthesis. Biochemistry, 1992, 31, 9008-9015.	2.5	13